Glucocorticoids treatment was administerd

to eighty two patients (90.1%) and the initial dose of prednisolone (PSL) was 0.7 ± 0.3 mg/kg/day. Cyclophosphamide (CY) was prescribed to 17 patients (18.7%). During the period of 55 ± 52 months after the onset of RRT, 18 vasculitis relapses occurred in 12 patients corresponding to an incidence rate of 0.048 episodes per person-year (95% CI: 0.029–0.076). Organ systems affected by relapses included lungs Adriamycin (n = 10), ears (n = 2), and eyes (n = 1). The duration from the onset of RRT to relapse was 49 ± 44 months and maximal duration was 156 months. At the relapse, 5 patients were not receiving immunosuppressive therapy and PSL (7.7 ± 3.4 mg/day) was prescribed for the remaining patients. Survival rates for 1, 3 and 5 years after RRT were 82.3%, 75.4% and 65.3%, respectively. The causes of deaths were infection (59.5%), cardiovascular event (24.3%), gastrointestinal bleeding (8.1%), malignancy (5.4%) and interstitial pneumonia (2.7%).

By Cox’s multivariate analysis, patient year (HR1.09, 95%CI:1.05–1.13) and pulmonary involvement (HR 3.95, 95%CI 1.77–8.83) were significant positive risks and the use of CY (HR 0.10, 95%CI 0.014–0.78) was a significant negative risk for mortality. Conclusion: Relapse could occur even after a long see more period from the onset of RRT. Infection was the most frequent cause of death and pulmonary involvement was related with mortality. It is important to clarify the optimal duration of maintenance therapy after RRT. PRATT RAYMOND D, LIN VIVIAN, GUSS CARRIE, GUPTA AJAY Rockwell Medical Introduction: Triferic (Ferric Pyrophosphate Citrate) is a novel iron salt that is soluble in dialysate and crosses the dialyzer membrane. Triferic, delivered via hemodialysate donates iron rapidly and directly to apo-transferrin, bypassing the reticuloendothelial system. Methods: In two, single blind, randomized placebo controlled clinical (CRUISE) Ribonuclease T1 trials, iron replete HD patients received either dialysate containing Triferic at 2 μM (110 μg iron/L, combined N = 299) or placebo (standard

dialysate, combined N = 300) for up to 48 weeks. Once randomized, no changes in ESA dose or administration of IV or oral iron were allowed. During the randomized treatment period, patients meeting pre-defined anemia management criteria (ESA dose change or IV iron administration for the development of iron deficiency) completed the study and were transitioned into an open label extension. Results: Dialytic transfer of Triferic with each HD was reliable and not significantly affected by dialyzer membrane type or reuse. A greater number of placebo subjects (57%) than Triferic subjects (46%) met pre-defined criteria for a change in anemia management and transitioned into the open-label study. IV iron was required by more subjects with placebo (12%) than Triferic (2%).